amlexanox has been researched along with Fatty Liver in 2 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reilly, SM | 1 |
| Chiang, SH | 1 |
| Decker, SJ | 1 |
| Chang, L | 1 |
| Uhm, M | 1 |
| Larsen, MJ | 1 |
| Rubin, JR | 1 |
| Mowers, J | 1 |
| White, NM | 1 |
| Hochberg, I | 1 |
| Downes, M | 1 |
| Yu, RT | 1 |
| Liddle, C | 1 |
| Evans, RM | 1 |
| Oh, D | 1 |
| Li, P | 1 |
| Olefsky, JM | 1 |
| Saltiel, AR | 1 |
| Cruz, VH | 1 |
| Arner, EN | 1 |
| Wynne, KW | 1 |
| Scherer, PE | 1 |
| Brekken, RA | 1 |
2 other studies available for amlexanox and Fatty Liver
| Article | Year |
|---|---|
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Topics: Aminopyridines; Animals; Anti-Allergic Agents; Anti-Obesity Agents; Cell Line; Diet, High-Fat; Energ | 2013 |
Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Topics: Aminopyridines; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fatty Liver; I-kappa B | 2018 |